drugset / Trial / NCT00014183
ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer
Phase 2
Completed
University of Maryland, Baltimore
National Cancer Institute (NCI) · collabUniversity of Maryland Greenebaum Cancer Center · collab
Treatment
Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of kidney cancer. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have recurrent or stage IV kidney cancer.
Timeline
- Start
- 2001-01
- Primary completion
- 2002-05
- Completion
- 2005-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | — | Oral |